Press Releases | Y-mAbs Therapeutics, Inc.

Year

Y-mAbs Announces Update on Naxitamab and Omburtamab in Neuroblastoma

NEW YORK , Oct. 16, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today

Oct 16, 2020

Y-mAbs Announces FDA Clearance of IND for its Lutetium-177 Labeled Omburtamab Antibody

NEW YORK , Oct. 14, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced

Oct 14, 2020

Y-mAbs’ Nivatrotamab for the Treatment of Patients with Neuroblastoma Granted Orphan Drug Designation and Rare Pediatric Disease Designation by FDA

NEW YORK , Oct. 07, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today

Oct 07, 2020

Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma

NEW YORK , Oct. 05, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today

Oct 05, 2020

Y-mAbs Announces Second Quarter 2020 Financial Results and Recent Corporate Developments

NEW YORK , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today

Aug 06, 2020

Y-mAbs Announces Completion of Submission of Omburtamab Biologics License Application to FDA

NEW YORK , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today

Aug 06, 2020

Y-mAbs to Announce Second Quarter 2020 Financial and Operating Results on August 6, 2020

NEW YORK , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the second quarter ended June 30, 2020 on Thursday, August 6, 2020 , after the close of the U.S. financial markets.

Aug 04, 2020

Y-mAbs Announces Data to be Presented at 2020 SIOP

NEW YORK , July 27, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, is pleased to

Jul 27, 2020

Y-mAbs Announces Update on SADA Technology and New Preclinical SADA Construct

NEW YORK , July 14, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today

Jul 14, 2020

Y-mAbs Announces Initiation of Submission of Omburtamab Rolling Biologics License Application to the FDA

NEW YORK , June 30, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today

Jun 30, 2020

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 21